6.32
price up icon0.96%   0.06
after-market Handel nachbörslich: 6.32
loading
Schlusskurs vom Vortag:
$6.26
Offen:
$6.25
24-Stunden-Volumen:
1.11M
Relative Volume:
0.78
Marktkapitalisierung:
$283.13M
Einnahmen:
$217.25M
Nettoeinkommen (Verlust:
$-50.92M
KGV:
-6.32
EPS:
-1
Netto-Cashflow:
$-100.85M
1W Leistung:
+5.51%
1M Leistung:
+35.62%
6M Leistung:
-53.77%
1J Leistung:
-69.00%
1-Tages-Spanne:
Value
$6.13
$6.585
1-Wochen-Bereich:
Value
$5.83
$6.585
52-Wochen-Spanne:
Value
$4.32
$25.42

Prothena Corporation Plc Stock (PRTA) Company Profile

Name
Firmenname
Prothena Corporation Plc
Name
Telefon
011-353-1-236-2500
Name
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Name
Mitarbeiter
163
Name
Twitter
@ProthenaCorp
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
PRTA's Discussions on Twitter

Vergleichen Sie PRTA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PRTA
Prothena Corporation Plc
6.32 283.13M 217.25M -50.92M -100.85M -1.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-28 Herabstufung BofA Securities Neutral → Underperform
2025-05-27 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-05-27 Herabstufung Jefferies Buy → Hold
2025-05-27 Herabstufung Oppenheimer Outperform → Perform
2024-12-20 Eingeleitet Chardan Capital Markets Buy
2024-01-30 Herabstufung BofA Securities Buy → Neutral
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-04-24 Eingeleitet SVB Securities Outperform
2023-01-27 Eingeleitet Piper Sandler Overweight
2022-11-04 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-09-28 Hochstufung BofA Securities Neutral → Buy
2021-11-19 Eingeleitet JMP Securities Mkt Outperform
2021-06-18 Hochstufung BofA Securities Underperform → Neutral
2021-06-08 Bestätigt Oppenheimer Outperform
2021-05-26 Eingeleitet Citigroup Buy
2021-02-26 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-02-12 Hochstufung Jefferies Hold → Buy
2021-02-02 Hochstufung BTIG Research Neutral → Buy
2020-12-07 Eingeleitet H.C. Wainwright Buy
2020-07-09 Hochstufung Oppenheimer Perform → Outperform
2019-11-19 Hochstufung Evercore ISI In-line → Outperform
2018-05-21 Herabstufung Barclays Equal Weight → Underweight
2018-04-23 Herabstufung Jefferies Buy → Hold
2018-04-05 Bestätigt Barclays Overweight
2017-11-20 Herabstufung Wedbush Outperform → Neutral
2017-09-29 Bestätigt BTIG Research Buy
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-08-17 Eingeleitet Evercore ISI Outperform
2017-07-11 Eingeleitet Jefferies Buy
2017-04-12 Eingeleitet Cantor Fitzgerald Overweight
2017-04-12 Eingeleitet Piper Jaffray Overweight
2017-03-02 Eingeleitet Instinet Buy
2016-12-21 Eingeleitet SunTrust Buy
2016-11-03 Eingeleitet Deutsche Bank Buy
2016-08-04 Bestätigt Barclays Overweight
2016-05-13 Eingeleitet Barclays Overweight
2016-02-19 Bestätigt Wedbush Outperform
2016-01-21 Eingeleitet Credit Suisse Outperform
Alle ansehen

Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten

pulisher
Jun 18, 2025

Prothena announces 63% workforce reduction following birtamimab halt - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena to cut workforce by 63% amid strategic review - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena announces corporate restructuring - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Corporate Restructuring - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

(PRTA) Trading Signals - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 14, 2025

Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com

Jun 14, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts Prothena FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Buys 27,887 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Prothena Co. plc (NASDAQ:PRTA) Short Interest Update - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Purchases 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

(PRTA) Technical Data - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 02, 2025
pulisher
May 31, 2025

Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN

May 31, 2025
pulisher
May 31, 2025

Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

May 31, 2025
pulisher
May 31, 2025

Chardan Capital Decreases Earnings Estimates for Prothena - Defense World

May 31, 2025
pulisher
May 30, 2025

Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World

May 30, 2025
pulisher
May 30, 2025

Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World

May 30, 2025
pulisher
May 29, 2025

Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World

May 29, 2025
pulisher
May 29, 2025

Bank of America Reaffirms “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World

May 29, 2025
pulisher
May 29, 2025

Prothena (NASDAQ:PRTA) Receives Underperform Rating from Bank of America - Defense World

May 29, 2025
pulisher
May 29, 2025

The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st

May 29, 2025
pulisher
May 29, 2025

BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 28, 2025

Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey

May 28, 2025
pulisher
May 28, 2025

BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World

May 28, 2025

Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Prothena Corporation Plc-Aktie (PRTA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
EcoR1 Capital, LLC
10% Owner
May 06 '25
Sale
7.64
1,984,053
15,164,712
5,304,596
EcoR1 Capital, LLC
10% Owner
May 05 '25
Sale
8.11
977,693
7,930,166
7,288,649
SCULLY WILLIAM P
10% Owner
Jan 14 '25
Buy
12.79
100,000
1,279,040
735,993
SCULLY WILLIAM P
10% Owner
Dec 18 '24
Buy
13.93
73,436
1,022,670
1,297,693
SCULLY WILLIAM P
10% Owner
Dec 31 '24
Buy
13.01
32,000
416,393
650,193
SCULLY WILLIAM P
10% Owner
Dec 20 '24
Buy
15.91
2,000
31,813
618,693
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):